Figure 2.
Figure 2. Event-free survival after standard-risk ALL with or without DS, by treatment era. (A) Event-free survival in a cohort of 5127 children treated for ALL on CCG therapeutic protocols between 1983 and 1995 with standard-risk features: a comparison by presence (ALL-DS) or absence (ALL-NDS) of Down syndrome. (B) Event-free survival in a cohort of 2118 children treated for ALL on CCG therapeutic protocols between 1983 and 1989 (Early Era) with standard-risk features: a comparison by presence (ALL-DS) or absence (ALL-NDS) of Down syndrome. (C) Event-free survival in a cohort of 3009 children treated for ALL on CCG therapeutic protocols between 1989 and 1995 (Recent Era) with standard-risk features: a comparison by presence (ALL-DS) or absence (ALL-NDS) of Down syndrome.

Event-free survival after standard-risk ALL with or without DS, by treatment era. (A) Event-free survival in a cohort of 5127 children treated for ALL on CCG therapeutic protocols between 1983 and 1995 with standard-risk features: a comparison by presence (ALL-DS) or absence (ALL-NDS) of Down syndrome. (B) Event-free survival in a cohort of 2118 children treated for ALL on CCG therapeutic protocols between 1983 and 1989 (Early Era) with standard-risk features: a comparison by presence (ALL-DS) or absence (ALL-NDS) of Down syndrome. (C) Event-free survival in a cohort of 3009 children treated for ALL on CCG therapeutic protocols between 1989 and 1995 (Recent Era) with standard-risk features: a comparison by presence (ALL-DS) or absence (ALL-NDS) of Down syndrome.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal